Exhibit 10.17


 


NOTE: PORTIONS
OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION
(“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]”
IN PLACE OF THE REDACTED LANGUAGE.


 


AMENDMENT TO JOINT VENTURE FOR R&D
AGREEMENT


 


This amendment to
Joint Venture for R&D Agreement (this “Amendment”) is entered into as of March 12, 2015, by and between Yissum
Research and Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”) and Intec Pharma Ltd.
(“Company”) (each to be referred to as a “Party” and together as the “Parties”).


 


		WHEREAS,	the Parties entered into a Joint
                                         Venture for R&D Agreement on June 1, 2000, which was extended and amended on October
                                         5, 2004 and July 13, 2005 (the agreement and its amendments shall be referred together
                                         in this Amendment as the “Agreement”); and



 


		WHEREAS,	in connection with the pending grant of a sublicense by the Company to “[***]”,
the Parties wish to amend the Agreement as set forth herein, to become effective only with respect to such sublicense to be granted
to “[***]”, as of the date such sublicense agreement
is executed with “[***]”;



 


NOW, THEREFORE, the Parties hereto, intending to be legally
bound, hereby agree as follows:


 


Except as specifically defined herein,
all terms used in this Amendment shall have the meaning ascribed to them in the Agreement.


 


		1.	Amendment



 


Effective as of the date of this Amendment, the Agreement shall
be amended as follows:


 


		1.1	Section 2 of Appendix E of the Agreement shall be
amended to read as follows:



 


“The Company will pay Yissum Sublicense Fees
during the Royalty Term at a rate of 15% of all Sublicense Consideration.”


 


		1.2	The following definitions will be added to Appendix
E of the Agreement:



 


“Royalty Term” means, on a country-by-country
basis, a period of 15 years from the date of the First Commercial Sale in each country.


 


“Sublicense Consideration”
shall mean any proceeds or consideration or benefit of any kind whatsoever that the Company or its Affiliate receives from a Sublicensee
to the extent that such is a direct result of the grant of a Sublicense or an option to obtain such Sublicense, other than research
and development funding that is actually used to cover the actual cost for research and development of a Product performed under
the Sublicense agreement.


 


		1.3	The term “Distributor” and all references thereto
                                         (including within the Net Sales definition) shall be deleted.



 


		1.4	The term “Product” shall be
                                         amended to read as follows:



 


“Product” shall mean
any product, process or service, the development, manufacture or sale of which exploits, comprises, contains, incorporates, is
related to, or based on any of the patents and/or patent applications set forth in Exhibit 1.4 attached hereto.


 


		1.5	The Parties acknowledge and agree that
                                         (i) the patent applications and patents set forth on Exhibit 1.5(a) are solely
                                         owned by Yissum and are subject to an exclusive license by Yissum to the Company pursuant
                                         to the Agreement; and (ii) the Company is the sole and exclusive owner of the patents
                                         and/or patent applications set forth in Exhibit 1.5(b) and all inventions disclosed
                                         or claimed in such patents and patent applications (collectively, “Intec Technology”)
                                         and Yissum acknowledges that it has no ownership right or interest in or claim with respect
                                         to such Intec Technology apart from the right to receive Royalties and Sublicense Fees
                                         as provided in the Agreement.



 




    	 



    	 



    

 


NOTE: PORTIONS
OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION
(“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]”
IN PLACE OF THE REDACTED LANGUAGE.


 


		1.6	Section 6(f) of the Agreement shall be amended to read as follows:



 


“Any Sublicensee may sublicense
the rights granted to such Sublicensee by the Company through multiple tiers without notice to or consent of Yissum, provided that
such Sublicensee is “[***]”.”


 


		1.7	The following Section 15(f) shall be added to the Agreement:



 


“15(f). In the
event that the Agreement is terminated for any reason whatsoever, then, at the request of “[***]”, if it is not
then in material default of the applicable Sublicense, Yissum shall enter into a new license agreement with
“[***]” on substantially the same terms as “[***]”, provided, however, that such terms shall
be amended, if necessary, to the extent required to ensure that such new agreement does not impose any obligations or
liabilities on Yissum which are not included in or are greater in scope than Yissum’s obligations or liabilities under
this Agreement”


 


		1.8	Yissum acknowledges and agrees that, notwithstanding the
provisions of Section 6(e), Section 6(f) and Section 11(f) of the Agreement, “[***]” nor a Sub-sublicensee of “[***]”
shall be required to enter into any direct undertaking or agreement of any kind with Yissum.



 


		2.	Effectiveness of Amended Agreement



 


The Agreement, as amended
hereby, shall continue in full force and effect as originally constituted and is hereby ratified and affirmed by the Parties.


 


IN WITNESS
WHEREOF, the parties have caused this Third Amendment to be executed by their duly authorized representatives as of the date first
written above.


 


	Yissum Research and Development	 	Intec Pharma Ltd.
	Company of the Hebrew University	 	 
	of Jerusalem Ltd.	 	 
	 	 	 
	By:	/s/ Yaacov Michlin and Shoshi Keynan	 	By:	/s/ Zeev Weiss
	 	 	 	 	 
	Name:	
        Yaacov Michlin – CEO and

        Shoshi Keynan – VP Licensing, Pharmaceuticals
	 	Name:	Zeev Weiss
	 	 	 	 	 
	Title:	 	 	Title:	 


 




    	 



    	 



    

 


NOTE: PORTIONS
OF THIS EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION
(“COMMISSION”). SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]”
IN PLACE OF THE REDACTED LANGUAGE.


 


Exhibit 1.4


 


	1.Patent	Yissum Research Development Company of the Hebrew University of Jerusalem Gastroretentive

Controlled Release Pharmaceutical
Dosage Forms -(Client Case:IN-1-IL) - (0047465)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	Israel	 	149853	 	1634914	 	20/11/2000	 	149853	 	01/04/2007	 	20/11/2018
	Patent Cooperation Treaty	 	PCT/IL00/00774	 	1635077	 	20/11/2000	 	WO 01/37812	 	31/05/2001	 	 
	Australia	 	16477/01	 	1635101	 	20/11/2000	 	783062	 	05/01/2006	 	20/11/2015
	Canada	 	2,392,361	 	1635119	 	20/11/2000	 	2,392,361	 	19/01/2010	 	20/11/2015
	Japan	 	2001-539427	 	1635127	 	20/11/2000	 	4679020	 	10/02/2011	 	10/02/2015
	United  States of America	 	10/157,325	 	1635143	 	20/11/2000	 	6,685,962	 	03/02/2004	 	03/08/2015
	South Africa	 	200204268	 	1635150	 	20/11/2000	 	2002/4268	 	26/11/2003	 	20/11/2015
	European Patent Office	 	00978993.4	 	1635168	 	20/11/2000	 	1235557	 	27/07/2005	 	 
	France	 	00978993.4	 	1635572	 	20/11/2000	 	1235557	 	27/07/2005	 	30/11/2015
	Germany	 	00978993.4	 	1635580	 	20/11/2000	 	60021604	 	27/07/2005	 	30/11/2015
	Spain	 	00978993.4	 	1635598	 	20/11/2000	 	1235557	 	27/07/2005	 	30/11/2015
	Switzerland	 	00978993.4	 	1635606	 	20/11/2000	 	EP1235557	 	27/07/2005	 	30/11/2015
	Ireland	 	00978993.4	 	1635630	 	20/11/2000	 	1235557	 	27/07/2005	 	30/11/2015
	Italy	 	00978993.4	 	1635648	 	20/11/2000	 	1235557	 	27/07/2005	 	30/11/2015
	United Kingdom	 	00978993.4	 	1635655	 	20/11/2000	 	1235557	 	27/07/2005	 	30/11/2015


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


	2.Patent	Intec Pharma Ltd. 

Method and Apparatus for Forming Delivery
Devices for Oral Intake of an Agent -(Client Case:IN-3-USP) -(0047512)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	United States of America	 	60/759,554	 	1636661	 	18/01/2006	 	 	 	 	 	 
	Patent Cooperation Treaty	 	IL2007/000070	 	1724418	 	18/01/2007	 	WO2007/083309	 	26/07/2007	 	 
	European Patent Office	 	07700757.3	 	1853217	 	18/01/2007	 	1981465	 	22/10/2008	 	31/01/2015
	Canada	 	2,637,655	 	1853225	 	18/01/2007	 	 	 	 	 	18/01/2015
	Israel	 	192896	 	1853233	 	18/01/2007	 	192896	 	28/09/2013	 	18/01/2017
	Japan	 	2008-550909	 	1853241	 	18/01/2007	 	5399715	 	01/11/2013	 	01/11/2016
	United States of America	 	12/087,888	 	1853258	 	18/01/2007	 	8,298,574	 	30/10/2012	 	30/04/2016
	United States of America	 	13/613,718	 	2181500	 	18/01/2007	 	8,753,678	 	17/06/2014	 	17/12/2017
	United States of America	 	13/800,471	 	2214433	 	18/01/2007	 	8,609,136	 	17/12/2013	 	17/06/2017
	Japan	 	2013-054912	 	2216375	 	18/01/2007	 	2013-129669	 	04/07/2013	 	 
	Israel	 	226561	 	2228767	 	18/01/2007	 	 	 	 	 	 
	Israel	 	226563	 	2229192	 	18/01/2007	 	 	 	 	 	 
	Israel	 	226564	 	2229205	 	18/01/2007	 	 	 	 	 	 
	United	 	 	 	 	 	 	 	 	 	 	 	 
	States of America	 	14/305,600	 	2275337	 	18/01/2007	 	
        US-2014-

        0360132
	 	11/12/2014	 	 


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


	3.Patent	Intec Pharma Ltd. 

A Gastro-Retentive System for the
Delivery of Macromolecules -(Client Case:IN-4-USP) -(0047513)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	United States of America	 	60/773,316	 	1636679	 	15/02/2006	 	 	 	 	 	 
	Patent Cooperation Treaty	 	IL2007/000212	 	1731967	 	15/02/2007	 	WO 2007/093999	 	23/08/2007	 	 
	European Patent Office	 	07713260.3	 	1859727	 	15/02/2007	 	1991210	 	19/11/2008	 	28/02/2015
	Canada	 	2,642,479	 	1859735	 	15/02/2007	 	2,642,479	 	19/08/2014	 	15/02/2015
	Israel	 	193450	 	1859743	 	15/02/2007	 	 	 	 	 	 
	United States of 

America	 	12/223,965	 	1859750	 	15/02/2007	 	
        US-2009-

        0304768
	 	10/12/2009	 	 


 


	4.Patent	Intec Pharma Ltd. 

Carbidopa/Lipodopa Gastroretentive
Drug Delivery -(Client Case:IN-7-IL) -(060812)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	Israel	 	208708	 	2051008	 	17/04/2009	 	 	 	 	 	 


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


	4.Patent	Intec Pharma Ltd. 

Carbidopa/Lipodopa Gastroretentive
Drug Delivery -(Client Case:IN-7-IL) -(060812)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	United States of America	 	12/937,955	 	2144590	 	17/04/2009	 	8,771,730	 	08/07/2014	 	08/01/2018
	Patent Cooperation Treaty	 	PCT/IB2009/005691	 	2153336	 	17/04/2009	 	WO 2009/144558	 	 	 	 
	Canada	 	2,721,493	 	2153341	 	17/04/2009	 	 	 	 	 	17/04/2015
	China	 	200980120103.9	 	2153353	 	17/04/2009	 	CN102149369A	 	10/08/2011	 	 
	European Patent Office	 	09754186.6	 	2153363	 	17/04/2009	 	2276473	 	26/01/2011	 	30/04/2015
	India	 	7638/DELNP/2010	 	2153372	 	17/04/2009	 	 	 	 	 	 
	Japan	 	2011-504573	 	2153395	 	17/04/2009	 	 	 	 	 	 
	Japan	 	 	 	2330464	 	 	 	 	 	 	 	 
	Republic of Korea	 	10-2010-7025481	 	2153405	 	17/04/2009	 	 	 	 	 	 
	South Africa	 	2010/07797	 	2153411	 	17/04/2009	 	2010/07797	 	27/07/2011	 	17/04/2015
	Hong Kong	 	11113197.1	 	2153823	 	17/04/2009	 	1158545	 	20/07/2012	 	17/04/2018
	United States of America	 	14/322,436	 	2286884	 	17/04/2009	 	
        US-2014-

        0314842
	 	23/10/2014	 	 
	United States of America	 	14/322,460	 	2286894	 	17/04/2009	 	
        US-2015-

        0010624
	 	08/01/2015	 	 


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


	5.Patent	Intec Pharma Ltd. 

ZALEPLON GASTRORETENTIVE DRUG DELIVERY
SYSTEM -(Client Case:IN-8-IL) -(060811)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	Israel	 	213376	 	2127779	 	19/10/2009	 	 	 	 	 	 
	Patent Cooperation Treaty	 	PCT/IB2009/007731	 	2153230	 	19/10/2009	 	WO 2010/064139	 	 	 	 
	China	 	200980153943.5	 	2153258	 	19/10/2009	 	CN102300463A	 	28/12/2011	 	19/10/2014
	European Patent Office	 	09830077.5	 	2153268	 	19/10/2009	 	2378883	 	26/10/2011	 	31/10/2014
	India	 	5067/DELNP/2011	 	2153278	 	19/10/2009	 	 	 	 	 	 
	South Africa	 	2011/04620	 	2153314	 	19/10/2009	 	2011/04620	 	28/03/2012	 	19/10/2015
	United States of America	 	13/132,899	 	2153326	 	19/10/2009	 	
        US-2012-

        0021051
	 	26/01/2012	 	 
	Japan	 	2014-231788	 	2320509	 	19/10/2009	 	 	 	 	 	 


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


	6.Patent	Intec Pharma Ltd. 

Accordion pill comprising levodopa
for an improved treatment of Parkinson’s Disease symptoms -(Client Case:IN-11-USP) -(060810)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	United States of America	 	61/408,985	 	2153012	 	01/11/2010	 	 	 	 	 	 
	
        Patent Cooperation Treaty
	 	PCT/IB2011/002888	 	2153034	 	01/11/2011	 	WO 2012/059815	 	10/05/2012	 	 
	Canada	 	2,815,959	 	2222633	 	01/11/2011	 	 	 	 	 	01/11/2015
	European Patent Office	 	11805936.9	 	2222641	 	01/11/2011	 	2635272	 	11/09/2013	 	30/11/2015
	India	 	4158/DELNP/2013	 	2222652	 	01/11/2011	 	 	 	 	 	 
	Israel	 	226000	 	2222662	 	01/11/2011	 	 	 	 	 	 
	United States of America	 	13/882,768	 	2222675	 	01/11/2011	 	
        US-2014-

        0017303
	 	16/01/2014	 	 


 


	7.Patent	Intec Pharma Ltd.

 “[***]”	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	“[***]”	 	“[***]”	 	“[***]”	 	“[***]”	 	 	 	 	 	 


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


	8.Patent	Intec Pharma Ltd. 

“[***]”	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	“[***]”	 	“[***]”	 	“[***]”	 	“[***]”	 	 	 	 	 	 


 





	9.Patent	Intec Pharma Ltd. 

“[***]”	 


 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	“[***]”	 	“[***]”	 	“[***]”	 	“[***]”	 	 	 	 	 	 


 





	10.Patent	Intec Pharma Ltd. 

“[***]”	 


 





	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	“[***]”	 	“[***]”	 	“[***]”	 	“[***]”	 	 	 	 	 	 


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


Exhibit 1.5 (a)


 


	1.Patent	Yissum Research Development Company of the Hebrew University of Jerusalem Gastroretentive Controlled Release Pharmaceutical
Dosage Forms -(Client Case:IN-1-IL) - (0047465)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	Israel	 	149853	 	1634914	 	20/11/2000	 	149853	 	01/04/2007	 	20/11/2018
	Patent Cooperation Treaty	 	PCT/IL00/00774	 	1635077	 	20/11/2000	 	WO 01/37812	 	31/05/2001	 	 
	Australia	 	16477/01	 	1635101	 	20/11/2000	 	783062	 	05/01/2006	 	20/11/2015
	Canada	 	2,392,361	 	1635119	 	20/11/2000	 	2,392,361	 	19/01/2010	 	20/11/2015
	Japan	 	2001-539427	 	1635127	 	20/11/2000	 	4679020	 	10/02/2011	 	10/02/2015
	United States of America	 	10/157,325	 	1635143	 	20/11/2000	 	6,685,962	 	03/02/2004	 	03/08/2015
	South Africa	 	200204268	 	1635150	 	20/11/2000	 	2002/4268	 	26/11/2003	 	20/11/2015
	European Patent Office	 	00978993.4	 	1635168	 	20/11/2000	 	1235557	 	27/07/2005	 	 
	France	 	00978993.4	 	1635572	 	20/11/2000	 	1235557	 	27/07/2005	 	30/11/2015
	Germany	 	00978993.4	 	1635580	 	20/11/2000	 	60021604	 	27/07/2005	 	30/11/2015
	Spain	 	00978993.4	 	1635598	 	20/11/2000	 	1235557	 	27/07/2005	 	30/11/2015
	Switzerland	 	00978993.4	 	1635606	 	20/11/2000	 	EP1235557	 	27/07/2005	 	30/11/2015
	Ireland	 	00978993.4	 	1635630	 	20/11/2000	 	1235557	 	27/07/2005	 	30/11/2015
	Italy	 	00978993.4	 	1635648	 	20/11/2000	 	1235557	 	27/07/2005	 	30/11/2015
	United Kingdom	 	00978993.4	 	1635655	 	20/11/2000	 	1235557	 	27/07/2005	 	30/11/2015


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


Exhibit 1.5 (b)


 


	2.Patent	Intec Pharma Ltd. 

Method and Apparatus for Forming Delivery
Devices for Oral Intake of an Agent -(Client Case:IN-3-USP) -(0047512)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	United  States of  America	 	60/759,554	 	1636661	 	18/01/2006	 	 	 	 	 	 
	Patent Cooperation Treaty	 	IL2007/000070	 	1724418	 	18/01/2007	 	WO2007/083309	 	26/07/2007	 	 
	European Patent Office	 	07700757.3	 	1853217	 	18/01/2007	 	1981465	 	22/10/2008	 	31/01/2015
	Canada	 	2,637,655	 	1853225	 	18/01/2007	 	 	 	 	 	18/01/2015
	Israel	 	192896	 	1853233	 	18/01/2007	 	192896	 	28/09/2013	 	18/01/2017
	Japan	 	2008-550909	 	1853241	 	18/01/2007	 	5399715	 	01/11/2013	 	01/11/2016
	United States of America	 	12/087,888	 	1853258	 	18/01/2007	 	8,298,574	 	30/10/2012	 	30/04/2016
	United States of  America	 	13/613,718	 	2181500	 	18/01/2007	 	8,753,678	 	17/06/2014	 	17/12/2017
	United States of America	 	13/800,471	 	2214433	 	18/01/2007	 	8,609,136	 	17/12/2013	 	17/06/2017
	Japan	 	2013-054912	 	2216375	 	18/01/2007	 	2013-129669	 	04/07/2013	 	 
	Israel	 	226561	 	2228767	 	18/01/2007	 	 	 	 	 	 
	Israel	 	226563	 	2229192	 	18/01/2007	 	 	 	 	 	 
	Israel	 	226564	 	2229205	 	18/01/2007	 	 	 	 	 	 
	United States of America	 	14/305,600	 	2275337	 	18/01/2007	 	
        US-2014-0360132
		11/12/2014	 	 


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


	3.Patent	Intec Pharma Ltd. 

A Gastro-Retentive System for the
Delivery of Macromolecules -(Client Case:IN-4-USP) -(0047513)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	United States of America	 	60/773,316	 	1636679	 	15/02/2006	 	 	 	 	 	 
	Patent Cooperation Treaty	 	IL2007/000212	 	1731967	 	15/02/2007	 	WO2007/093999	 	23/08/2007	 	 
	European Patent Office	 	07713260.3	 	1859727	 	15/02/2007	 	1991210	 	19/11/2008	 	28/02/2015
	Canada	 	2,642,479	 	1859735	 	15/02/2007	 	2,642,479	 	19/08/2014	 	15/02/2015
	Israel	 	193450	 	1859743	 	15/02/2007	 	 	 	 	 	 
	United States of America	 	12/223,965	 	1859750	 	15/02/2007	 	
        US-2009-0304768
	 	10/12/2009	 	 


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


	4.Patent	Intec Pharma Ltd. 

Carbidopa/Lipodopa Gastroretentive
Drug Delivery -(Client Case:IN-7-IL) -(060812)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	Israel	 	208708	 	2051008	 	17/04/2009	 	 	 	 	 	 
	United States of America	 	12/937,955	 	2144590	 	17/04/2009	 	8,771,730	 	08/07/2014	 	08/01/2018
	Patent Cooperation Treaty	 	PCT/IB2009/005691	 	2153336	 	17/04/2009	 	WO2009/144558	 	 	 	 
	Canada	 	2,721,493	 	2153341	 	17/04/2009	 	 	 	 	 	17/04/2015
	China	 	200980120103.9	 	2153353	 	17/04/2009	 	CN102149369A	 	10/08/2011	 	 
	European Patent Office	 	09754186.6	 	2153363	 	17/04/2009	 	2276473	 	26/01/2011	 	30/04/2015
	India	 	7638/DELNP/2010	 	2153372	 	17/04/2009	 	 	 	 	 	 
	Japan	 	2011-504573	 	2153395	 	17/04/2009	 	 	 	 	 	 
	Japan	 	 	 	2330464	 	 	 	 	 	 	 	 
	Republic of Korea	 	10-2010-7025481	 	2153405	 	17/04/2009	 	 	 	 	 	 
	South Africa	 	2010/07797	 	2153411	 	17/04/2009	 	2010/07797	 	27/07/2011	 	17/04/2015
	Hong Kong	 	11113197.1	 	2153823	 	17/04/2009	 	1158545	 	20/07/2012	 	17/04/2018
	United States of  America	 	14/322,436	 	2286884	 	17/04/2009	 	
        US-2014-0314842
	 	23/10/2014	 	 


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


	4.Patent	Intec Pharma Ltd. 

Carbidopa/Lipodopa Gastroretentive
Drug Delivery -(Client Case:IN-7-IL) -(060812)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	United States of America	 	14/322,460	 	2286894	 	17/04/2009	 	
        US-2015-0010624
	 	08/01/2015	 	 


 


	5.Patent	Intec Pharma Ltd. 

ZALEPLON GASTRORETENTIVE DRUG DELIVERY
SYSTEM -(Client Case:IN-8-IL) -(060811)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	Israel	 	213376	 	2127779	 	19/10/2009	 	 	 	 	 	 
	
        Patent Cooperation Treaty
	 	PCT/IB2009/007731	 	2153230	 	19/10/2009	 	WO2010/064139	 	 	 	 
	China	 	200980153943.5	 	2153258	 	19/10/2009	 	CN102300463A	 	28/12/2011	 	19/10/2014
	European Patent Office	 	09830077.5	 	2153268	 	19/10/2009	 	2378883	 	26/10/2011	 	31/10/2014
	India	 	5067/DELNP/2011	 	2153278	 	19/10/2009	 	 	 	 	 	 
	South Africa	 	2011/04620	 	2153314	 	19/10/2009	 	2011/04620	 	28/03/2012	 	19/10/2015


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


	5.Patent	Intec Pharma Ltd. 

ZALEPLON GASTRORETENTIVE DRUG DELIVERY
SYSTEM -(Client Case:IN-8-IL) -(060811)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	United States of America	 	13/132,899	 	2153326	 	19/10/2009	 	
        US-2012-0021051
	 	26/01/2012	 	 
	Japan	 	2014-231788	 	2320509	 	19/10/2009	 	 	 	 	 	 


 


	6.Patent	Intec Pharma Ltd. 

Accordion pill comprising levodopa
for an improved treatment of Parkinson’s Disease symptoms -(Client Case:IN-11-USP) -(060810)	 






 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	United States of America	 	61/408,985	 	2153012	 	01/11/2010	 	 	 	 	 	 
	Patent Cooperation Treaty	 	PCT/IB2011/002888	 	2153034	 	01/11/2011	 	WO2012/059815	 	10/05/2012	 	 
	Canada	 	2,815,959	 	2222633	 	01/11/2011	 	 	 	 	 	01/11/2015
	European Patent Office	 	11805936.9	 	2222641	 	01/11/2011	 	2635272	 	11/09/2013	 	30/11/2015
	India	 	4158/DELNP/2013	 	2222652	 	01/11/2011	 	 	 	 	 	 
	Israel	 	226000	 	2222662	 	01/11/2011	 	 	 	 	 	 


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS
EXHIBIT ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


	6.Patent	Intec Pharma Ltd. 

Accordion pill comprising levodopa
for an improved treatment of Parkinson’s Disease symptoms -(Client Case:IN-11-USP) -(060810)	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	United States of America	 	13/882,768	 	2222675	 	01/11/2011	 	
        US-2014-

        0017303
	 	16/01/2014	 	 


 


	7.Patent	Intec Pharma Ltd.

“[***]”	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	“[***]”	 	“[***]”	 	“[***]”	 	“[***]”	 	 	 	 	 	 


 


	8.Patent	Intec Pharma Ltd.



“[***]”

	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	“[***]”	 	“[***]”	 	“[***]”	 	“[***]”	 	 	 	 	 	 


  


	9.Patent	Intec Pharma Ltd.

“[***]”	 











 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	“[***]”	 	“[***]”	 	“[***]”	 	“[***]”	 	 	 	 	 	 


 




    	 



    	 



    

 


NOTE: PORTIONS OF THIS EXHIBIT
ARE THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST BY THE REGISTRANT TO THE SECURITIES AND EXCHANGE COMMISSION (“COMMISSION”).
SUCH PORTIONS HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION AND ARE MARKED WITH A “[***]” IN PLACE OF
THE REDACTED LANGUAGE.


 


	10.Patent	Intec Pharma Ltd. 

“[***]”	 



 


	Country	 	App. No.	 	Our 

Ref.	 	Filed	 	Patent No./ 

Publication No.	 	Grant Date/ 

Pub. Date	 	Next Renewal
	“[***]”	 	“[***]”	 	“[***]”	 	“[***]”